AstraZeneca PLC (LON: AZN) is poised to complete a substantial acquisition, purchasing Gracell Biotechnologies, a Chinese firm renowned for its innovative therapies targeting cancer and autoimmune diseases, in a deal worth $1.2 billion.
The acquisition, at a rate of $2 per share, will grant AstraZeneca access to cutting-edge platforms that have the potential to streamline manufacturing processes and advance the development of more efficient cell therapy treatments.
One of Gracell’s most promising assets is its T-cell therapy, known as GC012F, which holds significant potential for treating blood cancers and Lupus.
Susan Galbraith, AstraZeneca’s Executive Vice President of Oncology Research and Development, expressed in a company statement, “The proposed acquisition of Gracell will complement AstraZeneca’s existing capabilities and previous investments in cell therapy. GC012F will accelerate our cell therapy strategy in hematology, offering the potential for a leading-edge treatment for patients battling blood cancers, using a distinctive manufacturing approach, as well as exploring the possibilities of resetting the immune response in autoimmune diseases through cell therapy.”
The initial purchase of Gracell shares, priced at $2 each, is valued at $1 billion, with additional share acquisitions contingent upon achieving regulatory milestones, which could potentially elevate the deal’s overall value to $1.2 billion.
William Cao, Founder, Chairman, and CEO of Gracell, remarked, “We eagerly anticipate collaborating with AstraZeneca to expedite our shared mission of providing transformative cell therapies to a broader population of patients grappling with debilitating diseases.”
This strategic move by AstraZeneca aligns with its established partnerships with Chinese enterprises, including La Nova Medicines and Eccogene. AstraZeneca’s CEO, Pascal Soriot, has previously emphasized China’s receptiveness to investment.
Upon the anticipated closure of the deal in the first quarter of the forthcoming year, Gracell will operate as a subsidiary of AstraZeneca in both the United States and China.
Importantly, this acquisition does not impact AstraZeneca’s financial guidance for the past year.
As of Wednesday’s premarket trading, AstraZeneca remains stable, following its Friday closing price of 10,440p.
